Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Alternative exon usage in TRIM21 determines the antigenicity of Ro52/TRIM21 in systemic lupus erythematosus
Eduardo Gomez-Bañuelos, … , Michelle Petri, Felipe Andrade
Eduardo Gomez-Bañuelos, … , Michelle Petri, Felipe Andrade
Published August 30, 2022
Citation Information: JCI Insight. 2022;7(19):e163795. https://doi.org/10.1172/jci.insight.163795.
View: Text | PDF
Research Article

Alternative exon usage in TRIM21 determines the antigenicity of Ro52/TRIM21 in systemic lupus erythematosus

  • Text
  • PDF
Abstract

The origin and mechanisms of autoantigen generation in systemic lupus erythematosus (SLE) are poorly understood. Here, we identified SLE neutrophils activated in vivo by IFN as a prominent source of Ro52, also known as tripartite motif–containing protein 21 (TRIM21), a critical autoantigen historically thought to be primarily generated by keratinocytes in SLE. Different from mononuclear cells and keratinocytes, SLE neutrophils are enriched in several unique Ro52 species containing a core sequence encoded by exon 4 (Ro52Ex4) in TRIM21. Ro52Ex4 is the main target of anti-Ro52 antibodies and is found in 2 Ro52 variants (Ro52α and an isoform termed Ro52γ) upregulated in SLE neutrophils. Further analysis of Ro52γ revealed a subset of autoantibodies against a unique C-terminal domain (Ro52γCT) generated from a frameshift due to the lack of exon 6 in Ro52γ. Antibodies to Ro52Ex4 and Ro52γCT distinguish SLE patient subsets characterized by distinct clinical, laboratory, treatment, and transcriptional profiles that are not discerned by the “classical” anti-Ro52 antibodies. These studies uncover IFN-activated neutrophils as a key source of unique immunogenic forms of Ro52 in SLE. Moreover, the finding of Ro52Ex4 and Ro52γCT as core targets of anti-Ro52 antibodies focus interest on Ro52γ as the potential isoform toward which immunological tolerance is initially lost in SLE.

Authors

Eduardo Gomez-Bañuelos, M. Javad Wahadat, Jessica Li, Merlin Paz, Brendan Antiochos, Alessandra Ida Celia, Victoria Andrade, Dylan P. Ferris, Daniel W. Goldman, Erika Darrah, Michelle Petri, Felipe Andrade

×

Figure 4

Relationship between IFIT3 and Ro52 expression in neutrophils and PBMCs from patients with SLE and healthy controls.

Options: View larger image (or click on image) Download as PowerPoint
Relationship between IFIT3 and Ro52 expression in neutrophils and PBMCs ...
(A and B) Neutrophils (PMN) and PBMCs from 19 consecutive patients with SLE were analyzed by immunoblotting using antibodies to IFIT3, Ro52 (D-12 mouse monoclonal antibody), histone H3 (H3), and β-actin (loading controls). Representative data from 10 patients are shown. (C and D) Correlation between the expression of IFIT3 and Ro52 in PMN and PBMCs. The expression of Ro52 and IFIT3 was quantified by densitometry from the corresponding bands in A and B, and the values were fitted to a linear regression model. (E) PBMCs and PMN from 12 healthy controls (Ctrl) and 1 patient with SLE were analyzed by immunoblotting using antibodies to IFIT3, Ro52 (D-12 mouse monoclonal antibody), and H3 (loading control). Representative data from 6 healthy controls are shown. The SLE samples were included for comparison.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts